SVB Wealth LLC Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

SVB Wealth LLC raised its holdings in Hologic, Inc. (NASDAQ:HOLX) by 2.2% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,632 shares of the medical equipment provider’s stock after acquiring an additional 428 shares during the quarter. SVB Wealth LLC’s holdings in Hologic were worth $1,531,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. McGlone Suttner Wealth Management Inc. bought a new position in shares of Hologic in the 4th quarter worth $27,000. Allworth Financial LP boosted its position in shares of Hologic by 39.3% in the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 179 shares in the last quarter. Mather Group LLC. purchased a new position in Hologic during the 1st quarter worth $48,000. Massmutual Trust Co. FSB ADV raised its stake in Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 137 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt increased its holdings in shares of Hologic by 145.3% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 468 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of research reports. Royal Bank of Canada lifted their target price on Hologic from $81.00 to $82.00 and gave the stock a “sector perform” rating in a report on Tuesday. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Stephens began coverage on Hologic in a research note on Thursday, June 27th. They set an “overweight” rating and a $87.00 price objective for the company. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday. Finally, Argus boosted their price target on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, May 9th. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Hologic has a consensus rating of “Moderate Buy” and a consensus price target of $87.00.

Insider Transactions at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the transaction, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Hologic Trading Up 2.1 %

Shares of NASDAQ HOLX traded up $1.69 during trading on Tuesday, hitting $81.33. 536,510 shares of the company were exchanged, compared to its average volume of 1,611,134. The company has a fifty day moving average price of $74.66 and a 200-day moving average price of $75.08. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97. The firm has a market capitalization of $18.98 billion, a PE ratio of 41.36, a P/E/G ratio of 2.62 and a beta of 0.99. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $81.44.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. Hologic’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.93 earnings per share. As a group, equities research analysts expect that Hologic, Inc. will post 4.08 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.